Revolution in UTI Treatment
news,
AIBLABS,
September 14, 2023
Recce Pharmaceuticals, the Australian biotech pioneer, has announced the initiation of the Phase I/II clinical trials for their novel antibiotic compound, RECCE® 327. The first cohort has been dosed in this potentially game-changing study, focusing on the treatment of Urinary Tract Infections (UTIs).